Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. - Wikidata - awgldk - TriplyDB

Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma.

Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma.

http://www.wikidata.org/entity/Q33388306

about

Recurrent Glioblastoma: Where we stand A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care Bevacizumab and daily temozolomide for recurrent glioblastoma."One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.Recurrent high-grade glioma: a diagnostic and therapeutic challenge.Ependymoma stem cells are highly sensitive to temozolomide in vitro and in orthotopic models.Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma The efficacy of temozolomide for recurrent glioblastoma multiforme.Surgical resection of malignant gliomas-role in optimizing patient outcome.Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme The future of high-grade glioma: Where we are and where are we going.Dose-dense temozolomide: is it still promising?Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas Validation of the Effectiveness and Safety of Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas: 10-year Experience of a Single Institution.Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas : A Prospective Multicenter Study of Korean Patients.Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection.Standards of care for treatment of recurrent glioblastoma--are we there yet?Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience.Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial.Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology).Molecular markers in gliomas: impact for the clinician.Current and emerging molecular targets in glioma.Evolution of care for patients with relapsed glioblastoma.Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.Advances in malignant glioma drug discovery.Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.Metronomic chemotherapy for cancer treatment: a decade of clinical studies.The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.Incorporation of biomarkers in phase II studies of recurrent glioblastoma.Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro.The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis.Hepatotoxicity by combination treatment of temozolomide, artesunate and Chinese herbs in a glioblastoma multiforme patient: case report review of the literature.Toxicity of metronomic cyclophosphamide chemotherapy in a UK population of cancer-bearing dogs: a retrospective study.Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas.Metronomic chemotherapy with daily low-dose temozolomide and celecoxib in elderly patients with newly diagnosed glioblastoma multiforme: a retrospective analysis.A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma.Management and treatment recommendations for World Health Organization Grade III and IV gliomas.Temozolomide and MGMT forever?A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas.

P2860

Q26765042-9DDFDFE3-F579-450A-B369-8A0E5FB825DC Q26851160-11DAAF4F-E0CA-4A86-80B5-36C1A3D3D9D1 Q33396384-63C0D09F-0F8B-4D65-AE45-7C11F6815027 Q33405170-318760EA-1F2C-48CC-A50A-4E379DEEA7A1 Q33864058-52E6F7F5-93CD-4479-B36B-C29167DDAB52 Q33894470-44C64CEE-994D-46AD-9579-27B5920020C9 Q34062033-4AAEB1BE-2773-46EE-99E9-69B18C6B7741 Q34297519-194C16FE-82E0-42A0-BE5D-6A3AAABCC497 Q34324963-58B7696E-6B6C-4C4D-A280-6F4CD9736EAE Q35027024-91F325FC-3767-4437-96BE-D61651FFD395 Q35114090-23394E2A-F891-4221-8412-2C8B77885362 Q35943654-8E3970BF-47A8-492B-8009-CA4D54E2BBBC Q36201411-86F14BDD-8A68-47F3-B5CF-227CE5685439 Q36241711-8F77D60A-81B0-4D5D-B9D6-7E2028176F26 Q36306504-6D62ED30-B180-4911-87F2-B9AA7174ED25 Q36367414-9F92943D-5ECA-408F-9608-116CF86A27AF Q36500401-7167EE64-97B3-41D5-9D6B-B8E86F4F4B18 Q36544101-F821CA07-3AC7-44FD-8B09-37BB930559AF Q37366417-BDCD87E0-809C-4999-968E-8BA68FDC50FA Q37492175-A81B4C71-E6E5-44DF-8EEB-A8F68001B888 Q37526275-7D106FE4-1FCA-459A-89ED-D82E7B3AE335 Q37784456-4ECFC1D7-9D95-4D84-8790-128315C6E7DD Q37809861-91495AE1-1330-4BED-9D4B-BBCE370C22CE Q37952240-C66ECF48-6724-4513-A92C-A9527BEC260E Q37955091-EA082BD6-0C16-4CDA-8D71-EAA303891ADA Q38014949-BADBFD70-0665-4402-9C2B-A82D24BC077D Q38068203-F172E5C2-6E6A-4F68-A8A5-BFA819FF3A10 Q38087885-6473EA9A-76DD-4E85-81E9-EE5F40B322AD Q38205133-273EC008-4FC8-49D7-BBFF-9250B636F968 Q38298124-CFDC88E0-D09B-4DE3-9DC8-66AD5238B3C1 Q38409615-CDAD1019-2184-40FE-8137-08DA0C34DF98 Q38579564-9557D30D-E53A-4FBE-97BC-B1DA91972DED Q38926305-B843B71D-C352-4E69-9704-389EAFA2F5F5 Q39108682-4B05BFCB-C4EF-4CB4-A422-E8D56F46764C Q39524840-292628DB-B855-4884-9A33-D33660016114 Q40867629-8177A5C0-31AE-4C9B-A089-0646D39A7978 Q41701813-50E23D03-1564-4EAA-AAED-EC507961ECEC Q41706326-00497B8C-9C67-4665-AF0C-6B506D4BEA1A Q42426015-988737B7-D5F1-4E38-8401-452C97C280E2 Q45094655-24794E05-EAE2-4DF8-91D5-436B76E05594

P2860

Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma.

http://www.wikidata.org/entity/Q33388306

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Phase II trial of low-dose con ...... de for recurrent glioblastoma.

@ast

Phase II trial of low-dose con ...... de for recurrent glioblastoma.

@en

type

label

Phase II trial of low-dose con ...... de for recurrent glioblastoma.

@ast

Phase II trial of low-dose con ...... de for recurrent glioblastoma.

@en

prefLabel

Phase II trial of low-dose con ...... de for recurrent glioblastoma.

@ast

Phase II trial of low-dose con ...... de for recurrent glioblastoma.

@en

P1433

Q33388306-40D3566A-7643-4934-BDF9-DDE8C7064326

P1476

Q33388306-6F73E55E-CDA5-423E-81C4-D3AA7C5A6BB7

P2093

Q33388306-01C0F1D9-EC82-4783-BFA5-51028E3F8188

Q33388306-343B30C4-8A71-4D99-A01C-B4830CD09B42

Q33388306-40748EBE-DA53-4714-A29D-EC43B1BCCDF0

Q33388306-758ECEB5-110B-405E-BB9B-9532FF669D5F

Q33388306-76B7EA3D-79C6-4994-BC4D-EB8E77E7B454

Q33388306-82AEF94F-81E6-4649-98A1-A0DCB089DA7B

Q33388306-C422247C-3245-4336-9E61-437208BE8CEB

Q33388306-D2BC7AEB-5FA6-4B62-999F-28A451604C5D

P2860

Q33388306-040FFEE5-9CB2-43D7-A0B7-1F873B6E2A2F

Q33388306-0A70B756-033E-4AA6-B503-F3D67437B8F8

Q33388306-11004C6F-4508-4094-9950-CA7372D180B6

Q33388306-194E2DAB-F2D1-41C1-B2C2-9C3C07BBEFF9

Q33388306-1BB8F730-9C6F-496C-AC61-753100F2C4DD

Q33388306-1C2D3E7E-7602-4F53-BDBA-CC7551E94F94

Q33388306-24EE68CF-D57D-4AE5-AED7-F811B925FD43

Q33388306-2E11B3AD-DF24-4E83-82C0-DE0A57FEBC0E

Q33388306-37B1F54D-4596-4453-A514-F758517208BC

Q33388306-499C1213-E75F-453F-8130-CF14A5ED386F

P304

Q33388306-D19EE306-2DA2-4F49-B562-6B7CE4EEB55E

P31

Q33388306-72B051C7-9A0D-44BF-A677-A2ED281AC570

P356

Q33388306-6A2EE938-CF4A-4999-9505-A73AFC648C82

P433

Q33388306-186C5D84-11E0-40D3-AA32-B8A991427215

P478

Q33388306-5CC29695-0954-4333-9602-F3FEFAE249FF

P577

Q33388306-B575AEC4-29C1-46DD-9ECD-7A4308BF69AD

P5875

Q33388306-C1D99964-7CD1-4BA8-9328-A6971439042E

P698

Q33388306-CB5F9DD0-78B0-4E7D-A641-6BF6528DFE66

P921

Q33388306-93421F21-6D31-45DB-84B4-A0F36C7E7796

P932

Q33388306-DB59F5AD-3BEB-4AC1-A047-0E28B630CA63

P356

P1433

P1476

Phase II trial of low-dose con ...... de for recurrent glioblastoma.

@en

P2093

Do-Hyun Nam

http://www.w3.org/2001/XMLSchema#string

Doo-Sik Kong

http://www.w3.org/2001/XMLSchema#string

Jong Hyun Kim

http://www.w3.org/2001/XMLSchema#string

Jung-Il Lee

http://www.w3.org/2001/XMLSchema#string

Seung Myung Dong

http://www.w3.org/2001/XMLSchema#string

Sung Tae Kim

http://www.w3.org/2001/XMLSchema#string

Won Seog Kim

http://www.w3.org/2001/XMLSchema#string

Yeon-Lim Suh

http://www.w3.org/2001/XMLSchema#string

P2860

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.

Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients.

Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.

Monitoring health outcomes among patients with arthritis using the SF-36 Health Survey: overview.

Metronomic scheduling: the future of chemotherapy?

P304

289-296

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NEUONC/NOP030

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41486454

http://www.w3.org/2001/XMLSchema#string

P698

20167817

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

2940595

http://www.w3.org/2001/XMLSchema#string